Clinical trials: Transitional Cell Carcinoma of Urinary Bladder
Locally Advanced Bladder Urothelial Carcinoma, Metastatic Transitional Cell Carcinoma
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
This pilot phase II trial studies how well sapanisertib works in treating patients with bladder cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or other places in the body…
- Conditions
- Locally Advanced Bladder Urothelial Carcinoma, Metastatic Transitional Cell Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Carcinoma
- Trial name
- NCT03047213
- Testing
- Sapanisertib
- Where
- 20 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma, Urothelial Carcinoma
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
This is a comparative study using resected/ biopsied tumors samples collected from renal cell carcinoma and urothelial carcinoma patients who underwent surgical removal of lesions, followed by immune checkpoint blockade (ICB)…
- Conditions
- Renal Cell Carcinoma, Urothelial Carcinoma, Bladder Cancer, Ureter Cancer
- Trial name
- NCT03291028
- Testing
- Immune checkpoint inhibitor targeting PD1
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Fox Chase Cancer Center
Bladder Cancer
Bladder Washing Cytology for Detection of Urothelial Carcinoma Using Catheter or Flexible Cystoscope: Which is Better?
Urine cytology can be collected with spontaneous urine or by washing the bladder. It is commonly accepted among urologist that instrumental bladder washing is the method of choice.
- Trial name
- BWash (NCT05643807)
- Testing
- Flexible cystoscopy, Urinary catheter
- Where
- Switzerland
- Volunteers
- 414 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer
This phase II trial studies how well erlotinib hydrochloride works in Treating participants with muscle invasive urothelial cancer or urothelial cancer that has come back.
- Conditions
- Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma
- Trial name
- NCT00749892
- Testing
- Erlotinib Hydrochloride
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Transitional Cell Carcinoma of the Urothelial Tract, Bladder Cancer
Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract
The purpose of this clinical research study is to learn if patients who receive vinflunine plus best supportive care live longer than patients who receive best supportive care alone.
- Conditions
- Transitional Cell Carcinoma of the Urothelial Tract, Bladder Cancer, Bladder Neoplasms
- Trial name
- NCT00315237
- Testing
- vinflunine and best supportive care
- Where
- 10 sites in Canada
- Volunteers
- 364 people
- Sponsor
- Pierre Fabre Medicament
Bladder Cancer, Muscle-invasive Bladder Cancer
Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
The purpose of this research study is to test the effectiveness of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) in combination with pegfilgrastim followed by radical surgery in patients…
- Trial name
- NCT00808639
- Testing
- Methotrexate, Doxorubicin, vinblastine
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Dana-Farber Cancer Institute
Adenocarcinoma of the Bladder, Distal Urethral Cancer
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
This phase II trial is studying how well sorafenib works in treating patients with progressive regional or metastatic cancer of the urothelium.
- Conditions
- Adenocarcinoma of the Bladder, Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer
- Trial name
- NCT00112905
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Urothelial Carcinoma In Situ, Recurrent Bladder Urothelial Carcinoma
Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer
This phase II trial studies the safety and feasibility of utilizing acupuncture in patients with high-risk bladder cancer that has not spread to the surrounding muscle (non-muscle invasive) undergoing treatment with Intravesical…
- Conditions
- Bladder Urothelial Carcinoma In Situ, Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8
- Trial name
- NCT04496219
- Testing
- Acupuncture Therapy, BCG Solution, Best Practice
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Fred Hutchinson Cancer Center
Urinary Bladder Neoplasm, Transitional Cell Carcinoma
CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood
Transurethral resection of bladder tumor (TURBT) is usually performed in a piecemeal technique. Tumor fragmentation and cell spilling could be responsible for high recurrence rates.
- Conditions
- Urinary Bladder Neoplasm, Transitional Cell Carcinoma, Urogenital Neoplasms, Circulating Tumor Cell
- Trial name
- NCT04811846
- Testing
- Bipolar transurethral resection of bladder tumor (TURBT), Bipolar transurethral plasma kinetic vaporization of bladder tumor (PKVBT)
- Where
- 2 sites in Austria
- Volunteers
- 40 people
- Sponsor
- University Teaching Hospital Hall in Tirol
Bladder Cancer
Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer
Cisplatin is a very important agent for the treatment of TCC as it has a single agent response rate of approximately 15%. However, it has been most important as a part of combination chemotherapy, MVAC initially and now in…
- Trial name
- NCT00234494
- Testing
- Cisplatin, Gemcitabine, Bevacizumab
- Where
- 11 sites in United States
- Volunteers
- 45 people
- Sponsor
- Christopher Sweeney, MBBS
Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma
Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer
Objectives: Primary: Safety and tolerability of therapy with daratumumab in a cohort of patients with metastatic renal cell carcinoma and a cohort of patients with muscle invasive bladder cancer. Secondary: 1A.
- Conditions
- Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Malignant Urinary System Neoplasm, Metastatic Kidney Carcinoma
- Trial name
- NCT03473730
- Testing
- Biopsy, Daratumumab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Transitional Cell Carcinoma, Bladder Cancer
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
The use of a designed viral vector that can destroy cancer cells while leaving normal cells largely unharmed. The virus also stimulates an immunological response by producing a special factor (GM-CSF) to attract and promote the…
- Conditions
- Transitional Cell Carcinoma, Bladder Cancer, Carcinoma in Situ, Carcinoma in Situ Concurrent With Papillary Tumors
- Trial name
- BOND (NCT01438112)
- Testing
- CG0070 Adenovirus Vector, Control Arm: Quadruple Choice
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- CG Oncology, Inc.
Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer
Arsenic Trioxide in Treating Patients With Urothelial Cancer
Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have recurrent cancer of the bladder or urinary tract.
- Conditions
- Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Transitional Cell Carcinoma of the Bladder, Ureter Cancer
- Trial name
- NCT00009867
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer
This phase II trial studies the side effects and how well radiation therapy and durvalumab with or without tremelimumab work in treating participants with bladder cancer that cannot be removed by surgery, has spread to nearby…
- Conditions
- Bladder Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8
- Trial name
- NCT03601455
- Testing
- Durvalumab, External Beam Radiation Therapy, Tremelimumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Urothelial Carcinoma, Bladder Cancer
UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch
This comprehensive genomic analysis and biospecimen repository study incorporates Next Generation Sequencing (NGS) of archival tumor tissue from 200 subjects with metastatic urothelial cancer in support of several parallel goals.
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Urethral Cancer, Cancer of the Ureter
- Trial name
- NCT02643043
- Testing
- Biospecimen Collection
- Where
- 8 sites in United States
- Volunteers
- 219 people
- Sponsor
- Matthew Milowsky, MD
Urothelial Carcinoma, Bladder Cancer
Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer
This is a multi-institutional, randomized, placebo controlled, double-blinded phase II trial of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer who have…
- Trial name
- NCT02500121
- Testing
- Pembrolizumab
- Where
- 28 sites in United States
- Volunteers
- 108 people
- Sponsor
- Matthew Galsky
Metastatic Urothelial Carcinoma, Urothelial Cancer
A Real-world Study to Learn About of the Characteristics and Outcomes of Advanced or Metastatic Bladder Cancer Patients With Different Histologies
Bladder cancer (urothelial carcinoma) is a disease where cells in the bladder grow out of control. The bladder is an organ in the lower part of the body that stores urine.
- Conditions
- Metastatic Urothelial Carcinoma, Urothelial Cancer, Urothelial Carcinoma, Locally Advanced or Metastatic Urothelial Carcinoma
- Trial name
- NCT07897669
- Volunteers
- 5,122 people
- Sponsor
- Pfizer
Bladder Cancer
Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder
This trial will evaluate the efficacy and safety of combination chemotherapy (paclitaxel, carboplatin, and gemcitabine) prior to surgery in the treatment of patients with locally advanced transitional cell cancer of the bladder.
- Trial name
- NCT00136175
- Testing
- Paclitaxel, Carboplatin, Gemcitabine
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Michigan Rogel Cancer Center
Bladder Cancer, Bladder Urothelial Carcinoma
Bladder Perforation Post-TURBT: Definition, Incidence and Natural HistoryStudy
In view of sparse data of precise definition, risk factors, natural history and management of bladder perforation following Transurethral resection of bladder tumour (TURBT).
- Conditions
- Bladder Cancer, Bladder Urothelial Carcinoma, Trauma, Injuries
- Trial name
- TURBT-BP (NCT04129606)
- Testing
- Computed tomographic cystography
- Where
- Egypt
- Volunteers
- 300 people
- Sponsor
- Abdelwahab Hashem
Urinary Bladder Neoplasms, Bladder Cancer
A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer
The purpose of this study is to learn about the safety and effects of the study medicine (called avelumab) for the treatment of advanced bladder cancer.
- Conditions
- Urinary Bladder Neoplasms, Bladder Cancer, Bladder Tumors, Urothelial Carcinoma
- Trial name
- NCT05699135
- Testing
- Avelumab first-line maintenance
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- Pfizer